|
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
May 2023 |
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
|
The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes |
May 2023 |
Current Treatment Options in Oncology |
Myelodysplastic Syndromes (MDS) |
|
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal hemoglobinuria: Where we stand |
May 2023 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria |
May 2023 |
International Journal of Molecular Sciences |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
May 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
